2021
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, David E, Detterbeck F, Früh M, Gubens MA, Moore AC, Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB. Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline. Journal Of Clinical Oncology 2021, 40: 1356-1384. PMID: 34936470, DOI: 10.1200/jco.21.02528.Peer-Reviewed Original ResearchConceptsStage III NSCLCManagement of patientsCell lung cancerEvidence-based recommendationsLung cancerStage IIIEvidence-based guideline recommendationsUnresectable stage III NSCLCLiterature searchRecurrence-free survivalWorkup of patientsOutcomes of interestQuality of lifeAdvocacy expertsCommunity oncologyASCO guidelinesAdjuvant approachGuideline recommendationsSurgical managementMedical oncologyThoracic surgeryPulmonary oncologyExpert panel membersSystematic reviewPatients
2014
Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery
Hancock JG, Rosen JE, Antonicelli A, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery. The Annals Of Thoracic Surgery 2014, 99: 406-413. PMID: 25528723, DOI: 10.1016/j.athoracsur.2014.09.033.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositive surgical marginsCell lung cancerSurgical marginsR1 resectionNSCLC patientsResidual diseaseLung cancerNational Cancer Data BasePathologic stage IMicroscopic residual diseaseAdministration of chemotherapyOptimal treatment approachStage pIR1 patientsAdjuvant treatmentPostoperative administrationAdjuvant approachIncomplete resectionPostoperative radiationComplete resectionImproved survivalPI patientsPositive marginsSuperior survival
2008
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS)
Gralla RJ, Edelman MJ, Detterbeck FC, Jahan TM, Loesch DM, Limentani SA, Govindan R, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Supportive Care In Cancer 2008, 17: 307-313. PMID: 18781341, DOI: 10.1007/s00520-008-0489-y.Peer-Reviewed Original ResearchConceptsLung Cancer Symptom ScaleNon-small cell lung cancerQuality of lifeCancer Symptom ScaleCell lung cancerNeoadjuvant therapyPostsurgical evaluationLung cancerSymptom ScaleEarly-stage non-small cell lung cancerStage non-small cell lung cancerClinical stage IECOG performance statusSubgroup of patientsModalities of treatmentSignificant survival gainStable QOLConclusionsMost patientsNeoadjuvant trialsAdjuvant approachPerformance statusPreoperative chemotherapyComplete resectionStable symptomsSurvival gain